Haleon Completes Full Acquisition of Sino-American Tianjin SmithKline, Reinforcing Commitment to China's Booming OTC Market

　　【Pharmaceutical Network Industry DynamicsOn July 8, Haleon announced that it had completed the acquisition of the remaining 12% stake in its over-the-counter joint venture, Sino-American Tianjin SmithKline Pharmaceutical Co., Ltd. (hereinafter referred to as "Sino-American SmithKline"), on June 27. With this, Haleon has completed the acquisition of the original 45% stake owned by the Chinese party, and Sino-American SmithKline has officially become a wholly-owned subsidiary of Haleon.
 

Haleon focuses on categories such as pain management, respiratory health, skin health, and digestive health, with a series of brands including Fenbid, Sinutab, Bactroban, Voltaren, and Flixotide.
 

Haleon was independently listed on the London and New York Stock Exchanges after being spun off from GlaxoSmithKline in July 2022. Its business integrates the consumer health operations of GlaxoSmithKline, Novartis, and Pfizer, with brand history spanning over 170 years. Haleon holds a prominent position in the global consumer health market, particularly in areas such as sensitive oral care, gum health, denture care, and vitamins and mineral supplements (VMS).
 

As a "veteran" in China's pharmaceutical market, Haleon has achieved remarkable results since its establishment. Renowned for its strong marketing capabilities, it has successfully embedded well-known OTC brands such as Fenbid, Contac, Bactroban, and Voltaren into the minds of consumers, making them familiar household names. Through innovative advertising and marketing strategies, Haleon has helped consumers clearly understand the differences between OTC drug brands and manufacturers, effectively shaping consumer perceptions about medication. For example, among numerous pseudoephedrine hydrochloride manufacturers, Haleon created the significant IP character "Mr. Contac," enhancing consumer interaction and significantly boosting brand recognition and influence.
 

In recent years, with the intensification of population aging and the continuous upgrading of consumption levels, China's pharmaceutical market has shown tremendous appeal, becoming the world's second-largest health consumer market, only after the United States. As Chinese consumers' health awareness continues to rise, the demand for over-the-counter (OTC) drugs and health supplements keeps climbing. According to relevant data, the scale of China’s OTC drug market has been steadily increasing year by year, providing broad development opportunities for multinational pharmaceutical companies. Against the backdrop of policy changes such as adjustments to the National Essential Medicines List and the expansion of medical insurance coverage, although the growth rate of Haleon's robust OTC product line has slowed somewhat, its revenue remains stable at a high level, maintaining around 3.5 billion yuan in the past two years, demonstrating the strong market resilience and brand loyalty of its products.
 

Haleon's acquisition of the remaining equity in Sino-American SmithKline is an important strategic move after careful consideration. From the perspective of Haleon's own development, since becoming independent, although it has inherited several blockbuster OTC products and also incorporated Pfizer’s health care products, its overall revenue growth has not been strong enough, with poor performance in the European market and significant cost control pressure. In sharp contrast, Haleon’s performance in the Asia-Pacific region has been impressive, especially in the Chinese market, where products such as Caltrate and Bactroban have achieved double-digit growth. Therefore, the importance of the Chinese market to Haleon is self-evident, making it a key driver for the company’s global business growth.
 

After acquiring Sino-American SmithKline, Haleon can further integrate resources and leverage synergies. Sino-American SmithKline has a well-established sales network, with branches in Chengdu, Xi'an, Shanghai, Guangzhou, and other cities effectively driving product penetration in lower-tier markets. Meanwhile, the modern production lines at Sino-American SmithKline's Tianjin plant provide a solid foundation for localized manufacturing, enabling better adaptation to supply chain restructuring under favorable policies such as tariffs. After Haleon completes full ownership, brand integration will optimize resource allocation, enhance brand competitiveness in the Chinese market, and strengthen its position in the over-the-counter (OTC) pharmaceutical sector.
 

This acquisition is not only a significant milestone in the development journey of Haleon and Sino-American SmithKline, but also reflects multinational pharmaceutical companies' continued optimism towards China's pharmaceutical market. In recent years, many leading multinational pharmaceutical companies, including Bayer, Sanofi, and Novo Nordisk, have increased their investments in the Chinese market, which sufficiently demonstrates the growing importance of the Chinese market in the global pharmaceutical industry landscape. Haleon's full acquisition of Sino-American SmithKline will lay a solid foundation for its long-term development in the Chinese market and is expected to bring more high-quality health products and services to Chinese consumers, further promoting the prosperity and growth of China’s over-the-counter (OTC) drug market.
 

Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.